Results 171 to 180 of about 47,789 (213)

Novel non-peptidic neuropeptide Y Y 2 receptor antagonists

Bioorganic & Medicinal Chemistry Letters, 2004
Through SAR studies of a piperidinylindoline cinnamide HTS lead, the first potent, non-peptide, low molecular weight selective Neuropeptide Y Y2 (NPY Y2) antagonists have been synthesized. The SAR studies around the piperidinyl, the indolinyl, and the cinnamyl moieties are discussed.
Jill A, Jablonowski, Wenying, Chai, Xiaobing, Li, Dale A, Rudolph, William V, Murray, Mark A, Youngman, Scott L, Dax, Diane, Nepomuceno, Pascal, Bonaventure, Timothy W, Lovenberg, Nicholas I, Carruthers   +10 more
openaire   +2 more sources

Effect of a selective neuropeptide Y Y2 receptor antagonist, BIIE0246 on neuropeptide Y release

European Journal of Pharmacology, 2000
We have examined the selective neuropeptide Y Y(2) receptor antagonist, (S)-N(2)-[[1-[2-[4-[(R,S)-5,11-dihydro-6(6h)-oxodibenz[b, e]azepin-11-yl]-1-piperazinyl]-2-oxoethyl]cyclopentyl]acetyl ]-N-[2-[1 ,2-dihydro-3,5(4H)-dioxo-1,2-diphenyl-3-H-1,2, 4-triazol-4-yl]ethyl]-argininamid (BIIE0246) on neuropeptide release from rat hypothalamic slices in vitro.
P J, King, G, Williams, H, Doods, P S, Widdowson   +3 more
openaire   +2 more sources

Neuropeptide Y receptor antagonists.

IDrugs : the investigational drugs journal, 2005
A review of the patent literature for neuropeptide Y (NPY) antagonists is presented for the period of January 2000 to March 2001. This review focuses on antagonists of the Y(1) and Y(5) receptor subtypes, which have been of primary interest as anti-obesity agents.
openaire   +1 more source

Neuropeptide Y (NPY) Y1 Receptor Antagonists

2001
Neuropeptide Y(NPY), a 36-residue peptide amide isolated originally from porcine brain, exhibits a wide spectrum of central and peripheral activities mediated by at least six receptor subtypes denoted as Y1, Y2, Y3, Y4, Y5 and Y6 [1]. Investigations to date have implicated NPY in the pathophysiology of a number of diseases including feeding disorders ...
V. C. Dhawan, D. E. Mullins, W. T. Chance, S. Sheriff, M. Guzzi, E. M. Parker, A. Balasubramaniam   +6 more
openaire   +1 more source

Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer

Ca-A Cancer Journal for Clinicians, 2023
Laura A Huppert, Hope S Rugo
exaly  

Chimeric antigen receptor T‐cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice

Ca-A Cancer Journal for Clinicians, 2023

exaly  

Critical care management of chimeric antigen receptor T‐cell therapy recipients

Ca-A Cancer Journal for Clinicians, 2022
Alexander Shimabukuro-Vornhagen, Victoria Metaxa, Elie Azoulay   +2 more
exaly  

Breast Cancer Statistics, 2022

Ca-A Cancer Journal for Clinicians, 2022
Hyuna Sung, Kimberly D Miller, Rebecca L Siegel   +2 more
exaly  

Current treatment and recent progress in gastric cancer

Ca-A Cancer Journal for Clinicians, 2021
Smita S Joshi, Brian D Badgwell
exaly  

Neuropeptide Y receptors in pig spleen

Acta Physiologica Scandinavica, 1987
A, Härfstrand, J M, Lundberg, K, Fuxe
openaire   +2 more sources